Assignee
IKENA ONCOLOGY INC
US·13 granted patents·8 pending applications·23 citations·filing 2019–2024
Top patents by PatentIndex Score
21 records- 0198US11458149B1TEAD inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2020·Granted Oct 4, 2022·8 cites·24 claims
- 0298US11274082B2Tead inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2020·Granted Mar 15, 2022·9 cites·27 claims
- 0395US11760728B2Tead inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2022·Granted Sep 19, 2023·2 cites·21 claims
- 0495US11358969B2Indole AHR inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2020·Granted Jun 14, 2022·3 cites·20 claims
- 0592US11925651B2TEAD inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2022·Granted Mar 12, 2024·1 cites·27 claims
- 0687US2025122205A1Indole ahr inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 0780US12077542B2Indole AHR inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2022·Granted Sep 3, 2024·0 cites·20 claims
- 0880US2025011315A1Aryl hydrocarbon receptor (ahr) agonists and uses thereofIKENA ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 0977US12030876B2Aryl hydrocarbon receptor (AHR) agonists and uses thereofIKENA ONCOLOGY INC·Filed 2023·Granted Jul 9, 2024·0 cites·23 claims
- 1072US12459895B2MEK inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2023·Granted Nov 4, 2025·0 cites·20 claims
- 1170US12162884B2Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a] [1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine as aryl hydrocarbon receptor (AHR) inhibitorsIKENA ONCOLOGY INC·Filed 2023·Granted Dec 10, 2024·0 cites·24 claims
- 1269US11608329B2Aryl hydrocarbon receptor (AHR) agonists and uses thereofIKENA ONCOLOGY INC·Filed 2020·Granted Mar 21, 2023·0 cites·20 claims
- 1368US11878958B2MEK inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2023·Granted Jan 23, 2024·0 cites·22 claims
- 1466US11591339B2Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitorsIKENA ONCOLOGY INC·Filed 2020·Granted Feb 28, 2023·0 cites·19 claims
- 1560US11555026B2AHR inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2020·Granted Jan 17, 2023·0 cites·23 claims
- 1658US2024148740A1Combination of an ahr inhibitor with a pdx inhibitor or doxorubicineIKENA ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 1752US2021300912A1Aryl hydrocarbon receptor (ahr) agonists and uses thereofIKENA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1852US2023039711A1Ahr inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 1950US2023026232A1Ahr inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 2047US2022144839A1Indole ahr inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 2145US2021115416A1Pegylated kynureninase enzymes and uses thereof for the treatment of cancerIKENA ONCOLOGY INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when IKENA ONCOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →